Functional Precision Oncology: Testing Tumors with Drugs to Identify Vulnerabilities and Novel Combinations
Certis Oncology Solutions Recently Featured in Cancer Cell Journal for Innovation in Personalized Cancer Medicine
Certis Oncology Solutions is OLAW Assured
Certis Oncology Solutions, Inc. has obtained Office of Laboratory Animal WelfareOLAW assurance from the National Institutes of Health. Insurance ID: D22-01133.
How to Identify High-Quality Hits Early On: Your Guide to Ensuring Reproducible In Vitro Oncology Studies
In the past several decades, oncology drug development has had some major successes, from the approval of game-changing therapeutics such as rituximab and trastuzumab in the late-90s to the first tumor-agnostic approval for pembrolizumab in 2017.1...
A Growing Certis Oncology Solutions Expands Laboratory Footprint And Capabilities
San Diego, CA − San Diego-based preclinical translational science company is making moves. Certis Oncology Solutions, Inc., a precision oncology and translational science company, has expanded its operations and moved to a new facility at 5626...
Sarcomas vs. pharmaceutical science
THE RIGHT TUMOR MODELS BRING GREATER CERTAINTY TO DRUG CANDIDATE SELECTION
Making precision oncology more personal
FROM GENETIC TESTING FOR CANCER TO FUNCTIONAL, PATIENT-DERIVED MODELS Genetic testing for cancer has rapidly become an important and routine part of oncology treatment. It’s driven the rise of precision oncology, where clinicians seek to match the...
Predicting Therapeutic Response & Drug Resistance with O-PDX
AACR 2021 Poster #2929: Predicting Patient’s Therapeutic Response and Acquired Drug Resistance with Orthotopic Patient-Derived Xenografts (O-PDX) Patient-derived xenografts (PDX) are a commonly used in vivo model that can provide clinically...
The Subcutaneous Xenograft vs Orthotopic Xenograft Debate
Subcutaneous vs Orthotopic Xenografts: Identifying Clinically Relevant Models for Making More Accurate, Personalized Cancer Treatment Decisions In our last blog, we explored some of the current gaps in personalized medicine and how patient-derived...
Making More Accurate, Personalized Cancer Treatment Decisions With Clinically Relevant PDX Models
In the past few decades, researchers and clinicians have gained a deep understanding of the biology behind tumor growth and metastasis and the clinical course for many different types of cancers. Despite these advancements, cancers are still treated...
Precision Oncology as a Model for Bridging the “Valley of Death”
A persistent challenge in anti-cancer drug development remains translation from animal studies to human clinical trials. A shocking 57% of late-stage oncology trials fail due to inadequate efficacy. These failures amount to billions of dollars in...